androstenedione has been researched along with Bone Cancer in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (42.86) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jiao, Y; Ju, Y; Li, W; Liu, Y; Wang, S; Wang, Y; Zhang, B; Zhang, J; Zhang, M; Zhao, L; Zhao, M; Zhao, Y | 1 |
| Baelde, HJ; Bovée, JV; Cleton-Jansen, AM; Hogendoorn, PC; Karperien, M; van Beerendonk, HM | 1 |
| Brodie, A; Coombes, RC; Dowsett, M; Gazet, JC; Goss, P | 1 |
| Bajetta, E; Bombardieri, E; Ferrari, L; Martinetti, A; Massaron, S; Noberasco, C; Rimassa, L; Seregni, E; Zilembo, N | 1 |
| Dilley, WG; Haagensen, DE; Harvey, H; Lipton, A; Ruby, EJ; Santen, RJ; Wells, SA | 1 |
| Bélanger, A; Brochu, M; Cusan, L; Dupont, A; Labrie, F | 1 |
7 other study(ies) available for androstenedione and Bone Cancer
| Article | Year |
|---|---|
A novel androstenedione derivative induces ROS-mediated autophagy and attenuates drug resistance in osteosarcoma by inhibiting macrophage migration inhibitory factor (MIF).
Topics: Acetylcysteine; Adenine; Androstenedione; Autophagy; Bone Neoplasms; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; HMGB1 Protein; Humans; Macrophage Migration-Inhibitory Factors; Osteosarcoma; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; RNA Interference; RNA, Small Interfering; Secosteroids; Translocation, Genetic | 2014 |
Estrogen signaling is active in cartilaginous tumors: implications for antiestrogen therapy as treatment option of metastasized or irresectable chondrosarcoma.
Topics: Adult; Aged; Androstadienes; Androstenedione; Aromatase; Aromatase Inhibitors; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Chondrosarcoma; Dose-Response Relationship, Drug; Estrogen Antagonists; Estrogens; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Neoplasm Metastasis; Receptors, Estrogen; RNA, Messenger; Signal Transduction | 2005 |
4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer.
Topics: Adult; Aged; Androstenedione; Animals; Bone Neoplasms; Breast Neoplasms; Castration; Estradiol; Female; Humans; Injections, Intramuscular; Menopause; Mice; Middle Aged | 1984 |
Progress in the treatment and palliation of advanced breast cancer. Symposium proceedings. Jerusalem, 1993.
Topics: Androstenedione; Animals; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Palliative Care; Pamidronate | 1994 |
Serum markers of bone metastases in postmenopausal breast cancer patients treated with formestane.
Topics: Alkaline Phosphatase; Androstenedione; Antineoplastic Agents; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Calcium-Binding Proteins; Extracellular Matrix Proteins; Female; Humans; Matrix Gla Protein; Peptide Fragments; Postmenopause; Procollagen | 1997 |
Medical adrenalectomy with aminoglutethimide: clinical studies in postmenopausal patients with metastatic breast carcinoma.
Topics: Adrenal Cortex; Adrenalectomy; Aldosterone; Aminoglutethimide; Androstenedione; Bone Neoplasms; Breast Neoplasms; Drug Evaluation; Estrogens; Female; Follow-Up Studies; Humans; Hypophysectomy; Lung Neoplasms; Menopause; Middle Aged; Neoplasm Metastasis; Prolactin; Radiography; Remission, Spontaneous; Thyrotropin; Thyroxine; Time Factors | 1978 |
Endocrine effects of combined treatment with an LHRH agonist in association with flutamide in metastatic prostatic carcinoma.
Topics: Adenocarcinoma; Adrenal Cortex Hormones; Androgens; Androstane-3,17-diol; Androstenediol; Androstenedione; Androsterone; Anilides; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Dehydroepiandrosterone; Flutamide; Follicle Stimulating Hormone; Gonadotropin-Releasing Hormone; Humans; Hydrocortisone; Kinetics; Luteinizing Hormone; Male; Pregnenolone; Progesterone; Prolactin; Prostatic Neoplasms; Testosterone; Triptorelin Pamoate | 1988 |